Global Blood Cancer Diagnostics Market Size To Worth USD 16.27 Billion by 2030 | CAGR of 6.7%

Global Blood Cancer Diagnostics Market Size To Worth USD 16.27 Billion by 2030

According to a research report published by Spherical Insights & Consulting, the Global Blood Cancer Diagnostics Market Size to grow from USD 15.56 billion in 2021 to USD 16.27 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period.

Browse key industry insights spread across 200 pages with 100 market data tables and figures & charts from the report on  "Global Blood Cancer Diagnostics Market Size, Share, and COVID-19 Impact Analysis By Test (CBC Tests, CTC Tests, Liquid Biopsy, Blood Protein Testing, Bone Marrow Biopsy), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), by Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030". Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/blood-cancer-diagnostics-market

Blood cancer diagnostics is a technique that uses blood tests to detect the presence of a malignant tumour in a person's body by identifying various proteins, biomarkers, and certain indications from the blood cells. Efficient Diagnostic testing is used to confirm or rule out the presence of illness, monitor the disease's progression, schedule therapy, and evaluate the results. Tumour biopsies, imaging, endoscopic examinations, laboratory tests, genetic testing, and surgery are the main methods used to diagnose cancer.

COVID 19 Impact

A national emergency has been declared in numerous nations throughout the world due to the COVID 19 a pandemic In actuality, the pandemic has affected every aspect of cancer research and treatment, including monitoring and oncology care services in many nations throughout the world. Additionally, numerous local and national level restrictions on the movement of people and goods imposed by private and public authorities have negatively impacted the supply chain for pharmaceutical products and ingredients and are impeding market expansion. Additionally, the pandemic has caused a number of academic institutions to temporarily close, which has decreased the amount of cancer care products available to consumers.

The development of safe and effective therapies, the rise in the usage of nanoma medicine platforms, and the use of microRNA therapy are all contributing to the growth of the blood cancer market. The market will experience significant expansion as monoclonal antibodies and histone deacetylase inhibitors are added to the current treatment options. Clinicians favour biologic therapy using monoclonal antibodies like empliciti and darzlex because it has a well-known clinical profile. In addition, the rising incidence of blood cancer globally is probably going to support the market's overall growth. Haematological cancers like blood cancer are caused by a variety of genetic flaws. Medicines that alter the human immune system can be used to treat this illness and boost the effectiveness of radiation therapy, chemotherapy, platelet transfusions, and stem cell transplants. The market for blood cancer is also expected to rise as a result of the major industry participants' rising investments in infrastructure development. In addition to this, numerous government agencies also want to strengthen the healthcare infrastructure by providing adequate funding, which will accelerate market expansion.

The high cost of treating blood cancer will impede the market's expansion due to the low cost of treatment in developing nations. The global market for blood cancer will also be constrained by the absence of skilled professionals and adequate healthcare facilities in underdeveloped nations.

Test Type Insights

Liquid biopsy test segment to propel the market growth over the forecast period

On the basis of test, the global blood cancer market is segmented into CBC Tests, CTC Tests, Liquid Biopsy, Blood Protein Testing, Bone Marrow Biopsy. Among these, the liquid biopsy test segment holds the largest market share and is dominating the market over the forecast period. It has been proven that one of the most common diagnostic techniques is liquid biopsy, which has grown significantly in popularity in recent years.

End User Insights

Hospital Associated Labs is dominating the market over the forecast period

On the basis of end use, the global blood cancer market is segmented into Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others. Among tyhese, the Hospital Associated Labs are dominating the market and are going to continue the dominance over the upcoming years. The increase in hospital visits, the number of in-house diagnostic procedures conducted there, and growing public awareness of the benefits of early diagnosis are the key factors driving the segment's growth.

Regional Insights

North America is dominating the market with the largest market share over the forecast period

Due to the rising prevalence of blood cancer as well as the growing elderly population, North America is now outpacing all other areas in terms of the blood cancer market. The unhealthy lifestyles individuals lead and the rising need for biologic therapists will also contribute to the North American region's overall growth.

On the other hand, Asia Pacific is anticipated to see the fastest market expansion due to the increased release of cancer medications as well as significant investments made by the major market participants in the healthcare industry. Additionally, the expansion of government initiatives will support market growth.

Major vendors in the Global Blood Cancer Diagnostic Market include Argon Medical Devices, Inc., B. Braun Melsungen AG, Becton Dickinson and Company (C.R. Bard, Inc.), Boston Scientific Corporation, Cardinal Health, Inc., Cook Medical, Inc., Danaher Corporation (Leica Microsystem), Fujifilm Holdings Corp., Hologic, Inc., and Medtronic plc.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Blood Cancer Diagnostics Market based on the below-mentioned segments:

Blood Cancer Diagnostics Market, Test Analysis

• CBC Tests
• CTC Tests
• Blood Protein Testing
• Liquid Biopsy
• Bone Marrow Biopsy

Blood Cancer Diagnostics Market, End User Analysis

• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Others

Blood Cancer Diagnostics Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter